Dose Response Trial of Pergolide for Cocaine Dependence - 1

This study has been completed.

First Received: September 20, 1999 Last Updated: September 1, 2005 History of Changes

Sponsor:	National Institute on Drug Abuse (NIDA)
Collaborator:	Medical University of South Carolina
Information provided by:	National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:	NCT00000248

Purpose

The purpose of this study is to evaluate the efficacy and safety of pergolide for treatment of cocaine dependence.

Condition	Intervention	Phase
Cocaine-Related Disorders	Drug: Pergolide	Phase III

Study Type:	Interventional
Study Design:	Treatment
Official Title:	Dose Response Trial of Pergolide for Cocaine Dependence

Resource links provided by NLM:

Drug Information available for: Pergolide Pergolide mesylate

U.S. FDA Resources

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:

Side effects
Drug use
Retention
Cocaine withdrawal
Compliance
Effectiveness of medication for global improvements

Estimated Enrollment:	0
Study Start Date:	February 1996

Eligibility

Ages Eligible for Study:	21 Years to 50 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Please contact site for information.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00000248

Locations

United States, South Carolina
Medical University of South Carolina
Charleston, South Carolina, United States, 29425 742

Sponsors and Collaborators

National Institute on Drug Abuse (NIDA)

Medical University of South Carolina

Investigators

Principal Investigator:

Robert Malcolm, M.D.

Medical University of South Carolina

More Information

No publications provided

Study ID Numbers:	NIDA-08355-1, R01-08355-1
Study First Received:	September 20, 1999
Last Updated:	September 1, 2005
ClinicalTrials.gov Identifier:	NCT00000248 History of Changes
Health Authority:	United States: Federal Government

Additional relevant MeSH terms:

Cocaine-Related Disorders
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Mental Disorders
Physiological Effects of Drugs
Substance-Related Disorders

Disorders of Environmental Origin
Dopamine Agents
Dopamine Agonists
Pergolide
Pharmacologic Actions

ClinicalTrials.gov processed this record on November 27, 2009